Diet and Exercise in Pompe Disease

Not Applicable

Completed

Conditions: Pompe Disease
Glycogen Storage Disease Type II
Lysosomal Storage Diseases

Brief Summary: This study examines the effects of individualized diet and exercise plans on muscle strength, quality of life and respiratory function in Pompe disease. Subjects will be given a diet and exercise plan based on their individual needs, which will be followed for 16 weeks. Participants will also be provided with an activity tracker in order to track their exercise activities, access to an app that will allow them to input their daily food intake, and they will also come to the University of Florida for exercise tests, respiratory tests and questionnaires.

Detailed Description: Pompe is a rare disease, which occurs in approximately 1 in 40,000 births. It is a progressive and often fatal neuromuscular disorder resulting from a mutation in the gene for acid alpha- glucosidase (GAA), an enzyme necessary for the degradation of glycogen. Common symptoms include skeletal and smooth muscle myopathy, resulting in respiratory insufficiency, peripheral muscle weakness and generalized fatigue.

The progressive myopathy in Pompe disease seems to be influenced by increased muscle protein breakdown. The increased muscle protein breakdown leads to muscle wasting, weakness, increased resting energy expenditure and, consequently, increased fatigue. Our hypothesis is that a high protein, low carbohydrate diet associated with regular physical exercise will improve respiratory and peripheral muscle functions in Pompe disease.

In this study, we will investigate the effects of 16 weeks of planned diet and exercise in adolescent and young adult (15-55 years old) individuals with Pompe disease using an activity tracker.

The participant will be asked to come to the University of Florida 4 times throughout the study (screening, baseline, +/- 15 days of completing the diet and exercise plan and a follow up three months later) for exercise testing, quality of life questionnaires, respiratory function testing and blood draws.

Recruitment & Eligibility

Inclusion Criteria

Male or female subjects 15-55 years of age;
Have a diagnosis of Pompe disease, as defined by protein assay and/or DNA sequence of the acid alpha-glucosidase gene, with present clinical symptoms of the disease;
Be naïve to ERT or receiving ERT for at least eighteen months prior to beginning study;
Be able to walk at least 40m in the 6 minute walk test.
Willing to comply with study requirements

Exclusion Criteria

Arm && Interventions

Group	Intervention	Description
Diet and Exercise	Diet and Exercise	Patients will be given an individualized diet and exercise plan by a physical therapist and registered dietician. The diet and exercise plan will be carried out by the participant for 16 weeks. The exercise plan, an aerobic and strength training regimen, will be performed under the supervision of a personal trainer or certified exercise physiologist that is local to the participant. The participant will complete core-stabilizing exercises which can be performed at home or in an approved group class. The participant will wear an activity tracker at all times during this 16 week period, and will be asked to manually enter data into a phone app, such as daily food intake and weight.

Primary Outcome Measures

Name	Time	Method
Change in results of Brief Patient-Reported Outcomes Quality of Life (PROQOL)	Baseline, Month 4	The PROQOL assesses quality of life and health status to improve patient care
Change in FVC	Baseline, Month 4	Forced Vital Capacity (FVC) is the amount of air that can be forcefully exhaled after a full inspiration, and is an indicator of overall respiratory function
Change in overall QMT score	Baseline, Month 4	Quantitative muscle testing (QMT) measures peripheral muscle strength

Secondary Outcome Measures

Name	Time	Method
Compliance to diet and exercise plans	Month 4	Patients will be evaluated on their compliance to the diet and exercise plan they are assigned, by comparing activities assigned vs. activities completed

Locations (1): University of Florida Clinical Research Center
🇺🇸
Gainesville, Florida, United States